Sep. 13 at 1:46 AM
$GANX This was part of multiple interviews.
Future Partnership Plans for GT-02287 and the Magellan Platform in Parkinson’s Research
https://www.pharmexec.com/view/future-partnership-plans-gt-02287-magellan-platform-parkinson-research
Gene Mack: We’ll need to make several important decisions in the fourth quarter, once we receive the first relevant data set from Parkinson’s disease patients. Depending on the efficacy results and biomarker impact of GT-02287, we’ve been actively engaging with potential partners—including large pharma, mid-cap pharma, large biotech, and some mid-cap biotech companies. There’s a healthy level of interest among companies focused on neurodegenerative diseases.
That said, neurodegenerative disease remains a very challenging area. Unlike oncology or autoimmune diseases, conditions like Alzheimer’s and Parkinson’s have seen less progress, so there’s considerable risk aversion given the high failure rate in this space. We’ve been discussing this program with potential partners for several years, and now we’re approaching a critical stage.
